Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14)

By Adde Magdalena   Enblad Gunilla   Hagberg Hans   Sundström Christer   Laurell Anna  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 283-293

Humana Press, Inc

Access to resources Recommend Favorite

Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 9, 2013-11 ,pp. : 1412-1418

Bentham Science Publishers

Access to resources Recommend Favorite

PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas

By            

International Journal of Oncology, Vol. 48, Iss. 1, 2016-01 ,pp. : 253-260

Spandidos Publications

Access to resources Recommend Favorite

Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin’s lymphoma

By Schütt P.   Zimmermann K.   Derks C.   Ebeling P.   Welt A.   Poser M.   Hense J.   Metz K.   Anhuf J.   Sandmann M.   Neise M.   Moritz T.   Stuschke M.   Niederle N.   Seeber S.   Nowrousian Mohammad  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 3, 2009-03 ,pp. : 459-466

Springer Publishing Company

Access to resources Recommend Favorite

Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients

By Broccoli Alessandro   Stanzani Marta   Bandini Giuseppe   Bonifazi Francesca   Stefoni Vittorio   Pellegrini Cinzia   Derenzini Enrico   Gandolfi Letizia   Quirini Federica   Argnani Lisa   Tschon Marta   Casadei Beatrice   Baccarani Michele   Zinzani Pier Luigi  

Leukemia and Lymphoma, Vol. 54, Iss. 8, 2013-08 ,pp. : 1791-1793

Informa Healthcare

Access to resources Recommend Favorite